Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adalimumab biosimilar - Hong Kong King-Friendly Industrial

Next Previous
Drug Profile

Adalimumab biosimilar - Hong Kong King-Friendly Industrial

Alternative Names: adalimumab-aqvh; CHS-1420; YUSIMRY

Latest Information Update: 03 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus BioSciences
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Plaque psoriasis

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 27 Jun 2024 Hong Kong King-Friend Industrial acquires adalimumab biosimilar from Coherus Biosciences
  • 27 Jun 2024 Meitheal Pharmaceuticals and Hong Kong King-Friend Industry enters into an exclusive license agreement for adalimumab biosimilar in USA
  • 03 Jul 2023 Launched for Ankylosing spondylitis in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top